Letter to the Editor

The arguments of Aspirin for COVID-19 complications

Siukan Law 1*, Albert Wingnang Leung 2, Chuanshan Xu 3

1- Department of Science, School of Science and Technology, The Open University of Hong Kong, Ho Man Tin, Kowloon, Hong Kong.
2- School of Graduate Studies, Lingnan University, Tuen Mun, Hong Kong.
3- Key Laboratory of Molecular Target and Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China.

LETTER INFO

Letter history:
Received 27 December 2020
Received in revised form 30 December 2020
Accepted 31 December 2020

Keywords:
Aspirin
COVID-19 complications
Inflammatory response

Dear Editor

Recently, a research team from the School of Medicine at the University of Maryland reported that the usage of aspirin was associated with decreased mechanical ventilation, ICU admission, reduced lung injury, and in-hospital mortality in hospitalized patients with COVID-19. Four hundred and twelve (412) patients participated in this study within three months from March to July. Patients were given a low dosage of aspirin (75-81 mg/day), only 44% of patients required to have ventilator and 43% of patients admitted to ICU, also 47% of patients decreased the death rate after COVID-19 infection [1]. However, these investigations weren’t a randomized, double-blind, placebo-controlled trial [2].

Up to the present, an important complication of COVID-19 was increased risk of blood clotting for the patients. This was an inflammatory response of at least 30% or 70% of patients in ICU for the lining of blood vessels in the cardiovascular and alveoli in the lungs [3]. Aspirin was an anti-platelet agent which inhibited the formation of platelet by deactivating the activity of cyclooxygenase (COX) and making the irreversible reaction of acetylate serine 530 to generate the thromboxane serine 530 to generate the thromboxane A2, called “antithrombotic effect”. It also prohibited the virus replication by suppressing prostaglandin E2 (PGE2) in macrophages and up-regulated the production of type I interferon [4].

Indeed, there was no evidence to support aspirin for the prevention of virus (SARS-CoV-2). Aspirin had a life-threatening condition for children or teenagers because it enhanced the possibility of getting Reye's syndrome. Meanwhile, aspirin was not suitable for the treatment of DIC and patients with a thromboembolic situation as it would further increase the seriousness of blood bleeding lead to another side effect, for example, heart attack [5]. Currently, Leonard-Lorant I et al. suggested that a study of Troponin and D-Dimer thresholds to identify patients who should use prophylactic doses of aspirin with or without anticoagulation that confirm the non-harmful effect of aspirin on COVID-19 [6].

The above information demonstrates that aspirin is one of the potential candidates for COVID-19 complications. It possesses anti-inflammatory, anti-viral replication, and anti-coagulation of blood activities. However, much
more works need to be done including continuous safety assessments of aspirin against COVID-19. Nowadays, other treatments are being investigated in the recovery stage of COVID-19 such as azithromycin, tocilizumab, convalescent plasma, and REGN-CoV-2.

**Author contributions**

All authors contributed to the concept, acquisition and analysis of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.

**Conflicts of interest**

The authors have no conflicts of interest to disclose.

**Funding/support**

The authors received no funding source/grants or other materials support for this work.

**References**


